The diagnosis and management of NK/T-cell lymphomas

Table 3 Selected clinical studies on advanced-stage and relapsed/refractory NK/T-cell lymphomas

Study (reference)	Disease	No.	Treatment	ORR	CR	OS	PFS/DFS
Phase II [67]	Newly diagnosed stage IV, relapsed/refractory	38	SMILE	79%	45%	1-year: 55%	1-year: 53%
Retrospective [68]	Newly diagnosed stage IV	26	SMILE	NR	54%	5-year: 47%	4-year: 60%
Phase III [74]	Newly diagnosed, advanced stage	21	DDCP	95%	71%	1-year: 90%	1-year: 86%
Phase III [74]	Newly diagnosed, advanced stage	21	SMILE	67%	29%	1-year: 57%	1-year: 38%
Phase II [75]	Newly diagnosed, advanced stage	22	IMP L-asp	90%	65%	1-year: 76%	1-year: 43%
Phase II [76]	Relapsed/refractory	19	AspaMetDex	78%	61%	2-year: 40%	2-year: 40%
Retrospective [68]	Relapsed/refractory	44	SMILE	77%	66%	5-year: 52%	4-year: 68%
Retrospective [77]	Relapsed/refractory	13	MEDA	77%	61%	1-year: 69%	1-year: 62%
Retrospective [84]	Relapsed/refractory	7	Pembrolizumab	100%	71%	NR	NR

No. number of patients, ORR overall response rate, CR complete response, OS overall survival, PFS progression-free survival, DFS disease-free survival, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide, DDCP dexamethasone, gemcitabine, cisplatinum, pegasparaginase, IMP L-asp ifosfamide, methotrexate, etoposide, prednisolone, L-asparaginase, AspaMetDex L-asparaginase, methotrexate, dexamethasone, MEDA methotrexate, etoposide, dexamethasone, L-asparaginase